The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mirikizumab Promising for Plaque Psoriasis

Mirikizumab Promising for Plaque Psoriasis

April 10, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Recent research published in the British Journal of Dermatology found the inhibition of interleukin (IL) 23 led to significant skin clearance for patients with psoriasis lesions.1,2

You Might Also Like
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis
  • Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
Also By This Author
  • Sarilumab Is Effective for RA, Pregabalin Fails to Meet Study Endpoint & Ibuprofen Can Be Administered with a Patch

In the 16-week, phase 2 randomized, multi-center, double-blind, placebo-controlled efficacy and safety study, researchers examined three mirikizumab dosing regimens administered at Weeks 0 and 8, in patients with moderate to severe plaque psoriasis. Mirikizumab (LY3074828) is a humanized immunoglobulin G4 variant monoclonal antibody that binds to the p19 subunit of IL-23, but does not bind to IL-12.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To participate in the study, adult patients had to have had chronic plaque psoriasis vulgaris for at least six months prior to enrollment. Additionally, patients at baseline had to have: more than 10% of body surface area (BSA) involvement, an absolute Psoriasis Area and Severity Index (PASI) score of 12 or greater and a static Physician’s Global Assessment (sPGA) score of 3 or greater. Patients also had to have been judged as qualified for biologic therapy.

Patients were randomly assigned to receive either 30 mg (n=51), 100 mg (n=51) or 300 mg of mirikizumab (n=51), or a placebo (n=52). The baseline characteristics were similar among treatment groups. Patients were assessed at baseline, Weeks 8 and 16. The primary study objective was to establish the superiority of mirikizumab over placebo in achieving PASI90 at Week 16. The study had numerous secondary and exploratory objectives.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 16, a PASI90 was attained for all active treatment groups. The percentages of patients who achieved PASI90 were 29% for the 30 mg-treated group, 59% for the 100 mg-treated group, and 67% for the 300 mg-treated group. In the placebo group, 0% of patients attained PASI90 at Week 16.

Additionally, the proportion of patients who reported no itching, pain, burning or stinging symptoms and no impact of psoriasis on their quality of life at Week 16 was significantly higher in the mirikizumab-treated groups than in the placebo-treated group. This finding was considered clinically and statistically significant (P<0.001). The highest response rates were noted in the 100 mg mirikizumab-treated group and the 300 mg mirikizumab-treated group.

In this trial, the most common adverse effects were upper respiratory tract infections, injection-site pain, hypertension and diarrhea.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Mirikizumab is now in phase 3 clinical trials for the treatment of plaque psoriasis.3


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: mirikizumab, plaque psoriasis, skin

You Might Also Like:
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis
  • Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
  • Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.